Skip to content

TONIX PHARMACEUTICALS HOLDING CORP.: 10-Q filed 2013-05-07

What TONIX PHARMACEUTICALS HOLDING CORP. reported in its quarterly report filed 2013-05-07 (fiscal Q1 2013): 22 published measures, 56 facts as tagged in accession 0001144204-13-026856.

This filing

Form
10-Q (quarterly report)
Filed
2013-05-07
Fiscal period
fiscal Q1 2013
Accession
0001144204-13-026856 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All TONIX PHARMACEUTICALS HOLDING CORP. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-03-31594,475USD
At 2012-12-312,117,210USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2013-03-311,234,212USD
At 2012-12-311,158,502USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-03-31-639,737USD
At 2012-12-31958,708USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-01-01 to 2013-03-31-2,001,203USD90
2007-06-07 to 2013-03-31-17,845,483USD2125
2012-01-01 to 2012-03-31-2,014,988USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-01-01 to 2013-03-31-1,361,629USD90
2007-06-07 to 2013-03-31-11,565,332USD2125
2012-01-01 to 2012-03-31-1,777,614USD91

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2013-01-01 to 2013-03-310USD90
2007-06-07 to 2013-03-3178,535USD2125
2012-01-01 to 2012-03-310USD91

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-01-01 to 2013-03-310USD90
2007-06-07 to 2013-03-3112,127,895USD2125
2012-01-01 to 2012-03-314,237,895USD91

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2013-01-01 to 2013-03-31-22USD90
2007-06-07 to 2013-03-31-138,824USD2125
2012-01-01 to 2012-03-31-22USD91

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2013-03-3142,756USD
At 2012-12-3146,894USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2013-01-01 to 2013-03-31392,323USD90
2007-06-07 to 2013-03-311,944,194USD2125
2012-01-01 to 2012-03-310USD91

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2013-01-01 to 2013-03-31-2,001,225USD90
2007-06-07 to 2013-03-31-14,869,836USD2125
2012-01-01 to 2012-03-31-1,160,365USD91

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-03-31491,430USD
At 2012-12-312,010,049USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-03-311,216,788USD
At 2012-12-311,138,792USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2013-03-31870,096USD
At 2012-12-31825,837USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2013-01-01 to 2013-03-312,001,225USD90
2007-06-07 to 2013-03-3114,869,836USD2125
2012-01-01 to 2012-03-311,160,365USD91

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2013-01-01 to 2013-03-31740,629USD90
2007-06-07 to 2013-03-315,275,891USD2125
2012-01-01 to 2012-03-31397,628USD91

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2013-03-312,159,130shares
At 2012-12-312,159,130shares

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2013-03-31346,692USD
At 2012-12-31309,800USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2013-03-3167,691USD
At 2012-12-31224,659USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2013-01-01 to 2013-03-311,260,596USD90
2007-06-07 to 2013-03-319,593,945USD2125
2012-01-01 to 2012-03-31762,737USD91

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2013-01-01 to 2013-03-314,138USD90
2007-06-07 to 2013-03-3135,779USD2125
2012-01-01 to 2012-03-312,354USD91

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2013-01-01 to 2013-03-310USD90
2007-06-07 to 2013-03-316,932,894USD2125
2012-01-01 to 2012-03-314,387,895USD91

Inspect the source

Entity
TONIX PHARMACEUTICALS HOLDING CORP. / CIK 0001430306
Captured
2026-09-20T09:02:25.703Z
SEC response SHA-256
c58b9668b329c3fe1faf138366f8781d658cf50824bc6e133ce4aa43029ca9ed

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001430306.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))